CYTOKINETICS, INC 23282W605 05/14/2025 Election of Class III Director to serve for a three-year term and until their successors are duly elected and qualified: John T. Henderson DIRECTOR ELECTIONS ISSUER 980392 0 FOR 980392 FOR CYTOKINETICS, INC 23282W605 05/14/2025 Election of Class III Director to serve for a three-year term and until their successors are duly elected and qualified: B. Lynne Parshall DIRECTOR ELECTIONS ISSUER 980392 0 FOR 980392 FOR CYTOKINETICS, INC 23282W605 05/14/2025 Election of Class III Director to serve for a three-year term and until their successors are duly elected and qualified: Muna Bhanji DIRECTOR ELECTIONS ISSUER 980392 0 FOR 980392 FOR CYTOKINETICS, INC 23282W605 05/14/2025 To approve the amendment and restatement of the Cytokinetics Amended and Restated 2004 Equity Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under such plan by 5,000,000 shares of common stock and (ii) provide for limitations on the maximum grant value that non-executive directors may receive under such plan of $1,000,000 for annual grants to continuing directors and $1,250,000 for the initial grant to new directors. COMPENSATION ISSUER 980392 0 FOR 980392 FOR CYTOKINETICS, INC 23282W605 05/14/2025 To approve an amendment to Cytokinetics, Incorporated's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common available for issuance by Cytokinetics, Incorporated from 163,000,000 to 326,000,000 shares of common stock. CAPITAL STRUCTURE ISSUER 980392 0 FOR 980392 FOR CYTOKINETICS, INC 23282W605 05/14/2025 To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as Cytokinetics, Incorporated's independent registered publicaccounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 980392 0 FOR 980392 FOR CYTOKINETICS, INC 23282W605 05/14/2025 To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement. COMPENSATION ISSUER 980392 0 FOR 980392 FOR BioCryst Pharmaceuticals, Inc. 09058V103 06/12/2025 Vote Board of Director: Steven Galson, MD, MPH DIRECTOR ELECTIONS ISSUER 3846154 0 FOR 3846154 FOR BioCryst Pharmaceuticals, Inc. 09058V103 06/12/2025 Vote Board of Director: Alan Levin DIRECTOR ELECTIONS ISSUER 3846154 0 FOR 3846154 FOR BioCryst Pharmaceuticals, Inc. 09058V103 06/12/2025 To ratify the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2025. AUDIT-RELATED ISSUER 3846154 0 FOR 3846154 FOR BioCryst Pharmaceuticals, Inc. 09058V103 06/12/2025 To hold a non-binding, advisory vote regarding executive compensation. COMPENSATION ISSUER 3846154 0 FOR 3846154 FOR BioCryst Pharmaceuticals, Inc. 09058V103 06/12/2025 To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan. CAPITAL STRUCTURE ISSUER 3846154 0 FOR 3846154 FOR